| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 838.50 | 1.8% | 5.2% |
| Total Income | 838.50 | 1.8% | 5.2% |
| Expenditure | 903.80 | 11.1% | 15.1% |
| PBT | -40.70 | 285.8% | 8240.0% |
| Net Profit | -52.00 | 461.1% | 784.2% |
| OPM | -7.79% | 9.03pp | 9.28pp |
| NPM | -6.20% | 7.95pp | 7.15pp |
| EPS | -0.41 | 2150.0% | 920.0% |
Bruker Reports Q2 2026 Financial Results with Organic Revenue Growth
04 Aug 2026 · 4 Aug, 4:38 pm
Summary
Bruker Corporation announced its financial results for the second quarter of 2026, reporting revenue of $838.5 million, a 5.2% increase year-over-year, with organic growth of 2.8%. The company saw strong performance in its Scientific Instruments segment with 10% organic bookings growth. Non-GAAP diluted earnings per share reached $0.49, up from $0.32 in the prior year. Bruker is updating its full-year 2026 guidance, projecting revenues between $3.54 to $3.57 billion and non-GAAP EPS between $2.10 to $2.15, indicating an expected year-over-year increase of 15% to 17%. Management expressed confidence in a gradual market recovery and anticipates significant organic margin expansion and non-GAAP EPS growth in both 2026 and 2027.
Key Highlights
- 1
Bruker reported Q2-26 revenue of $838.5 million, an increase of 5.2% year-over-year, with organic growth of 2.8%.
- 2
The Bruker Scientific Instruments (BSI) segment achieved 10% organic bookings growth year-over-year in Q2-26.
- 3
Non-GAAP diluted EPS for Q2-26 was $0.49, a significant increase from $0.32 in the prior year's second quarter.
- 4
For the first half of 2026, total revenue was $1.7 billion, up 3.9% compared to the first half of 2025.
- 5
Bruker is updating its FY2026 guidance for currency and tax, now expecting revenues between $3.54 to $3.57 billion.
- 6
The company anticipates non-GAAP EPS for FY26 to be between $2.10 to $2.15, representing a 15% to 17% year-over-year increase.
Management Comments
Frank H. Laukien
We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieved strong order bookings growth for our differentiated products and solutions in the semiconductor tools, energy research and biopharma markets. In our academic and medical research business, US academic demand remained soft in Q2, while aca/gov bookings in Europe and China were up strongly. We are gaining confidence in a gradual market recovery, and we anticipate significant organic margin expansion and non-GAAP EPS growth not only this year, but in 2027 as well.
Informational and educational content only. Not investment advice.